Proceedings: Vaginal cytologic evaluation as a predictive test on hormone dependency and responsiveness to progestogens of endometrial adenocarcinoma.

Abstract

Progestogens seem to be very useful not only as a complement to combined radiosurgical therapy of localized and endometrial adenocarcinoma but also as an exclusive treatment of recurrent or metastatic cancers. Exclusive high dosage medroxyprogesterone treatment brings about a significant remission in almost 50% of the recurrent or metastatic endometrial adenocarcinomata. Vaginal cytological evaluation before and during therapy has a striking prognostic value. In 57% of the patients presenting an estrogenic vaginal smear (68% of total patient number) before medroxyprogesterone treatment a significant tumor remission is observed. Progestational treatment changing an estrogenic smear to an intermediate or to an atrophic one or bringing an intermediate smear to atrophy induces a 92% even a 100% signigicant remission rate. Return of the vaginal smear to an estrogenic aspect after withdrawing the medroxyprogesterone therapy or even during this treatment announces a new progression of the adenocarcinoma.(FULL TEXT)